Search

Your search keyword '"Coyle, Luke"' showing total 13 results
Start Over Author "Coyle, Luke" Publication Year Range Last 3 years
13 results on '"Coyle, Luke"'

1. Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication

Author

Dambra, Richard, Matter, Andrea, Graca, Kaitlynn, Akhand, Saeed Salehin, Mehta, Saurin, Bell-Cohn, Ashlee, Swenson, Joyce M., Abid, Sadia, Xin, Dongyue, Lewis, Cedric, Coyle, Luke, Wang, Min, Bunosso, Kathleen, Maugiri, Michelle, Ruiz, Richard, Cirillo, Corey M., Fogal, Birgit, Grimaldi, Christine, Vigil, Adam, Wood, Charles, and Ashour, Joseph

Published
2023
Full Text
View/download PDF

2. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL

Author

Greenwood, Matthew, Trahair, Toby, Sutton, Rosemary, Osborn, Michael, Kwan, John, Mapp, Sally, Howman, Rebecca, Anazodo, Antoinette, Wylie, Brenton, D'Rozario, James, Hertzberg, Mark, Irving, Ian, Yeung, David, Coyle, Luke, Jager, Amanda, Engeler, Dan, Venn, Nicola, Frampton, Chris, Wei, Andrew H., Bradstock, Kenneth, and Dalla-Pozza, Luciano

Published
2021
Full Text
View/download PDF

4. A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity

Author

Gall, Louis, primary, Jardi, Ferran, additional, Lammens, Lieve, additional, Piñero, Janet, additional, Souza, Terezinha M., additional, Rodrigues, Daniela, additional, Jennen, Danyel G. J., additional, de Kok, Theo M., additional, Coyle, Luke, additional, Chung, Seung‐Wook, additional, Ferreira, Sofia, additional, Jo, Heeseung, additional, Beattie, Kylie A., additional, Kelly, Colette, additional, Duckworth, Carrie A., additional, Pritchard, D. Mark, additional, and Pin, Carmen, additional

Published
2023
Full Text
View/download PDF

5. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Author

Baggio, Diva, primary, Wellard, Cameron, additional, Chung, Eliza, additional, Talaulikar, Dipti, additional, Keane, Colm, additional, Opat, Stephen, additional, Giri, Pratyush, additional, Minson, Adrian, additional, Cheah, Chan Yoon, additional, Armytage, Tasman, additional, Lee, Denise, additional, Chong, Geoffrey, additional, Johnston, Anna, additional, Cochrane, Tara, additional, Waters, Neil, additional, Hamad, Nada, additional, Wood, Erica M., additional, Hawkes, Eliza A., additional, Balendra, John, additional, Barraclough, Allison, additional, Berkahn, Leanne, additional, Bosco, Annmarie, additional, Carradice, Duncan, additional, Chuah, Hun, additional, Coyle, Luke, additional, Crassini, Kyle, additional, Kenealy, Melita, additional, Ku, Matthew, additional, Leung, Teresa, additional, Manos, Kate, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Palfreymen, Emma, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Simpson, Jock, additional, Trotman, Judith, additional, Viiala, Nicholas, additional, and Wight, Joel, additional

Published
2022
Full Text
View/download PDF

7. Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Author

Giri, Pratyush, primary, Patil, Sushrut, additional, Ratnasingam, Sumita, additional, Prince, H. Miles, additional, Milliken, Samuel, additional, Briones Meijide, Javier, additional, Coyle, Luke, additional, Van Der Poel, Marjolein, additional, Mulroney, Carolyn M., additional, Farooqui, Mohammed Z. H., additional, Wong, Hansen, additional, Desai, Rajendra, additional, Zugmaier, Gerhard, additional, Mergen, Noemi, additional, and Cannell, Paul, additional

Published
2022
Full Text
View/download PDF

10. Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome

Author

Shen, Yandong, primary, Coyle, Luke, additional, Kerridge, Ian, additional, Stevenson, William, additional, Arthur, Christopher, additional, McKinlay, Naomi, additional, Fay, Keith, additional, Ward, Christopher, additional, Greenwood, Matthew, additional, Best, Oliver Giles, additional, Solterbeck, Ann, additional, Guminski, Alexander, additional, Shumack, Stephen, additional, and Mulligan, Stephen P., additional

Published
2021
Full Text
View/download PDF

13. Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication.

Author

Dambra R, Matter A, Graca K, Akhand SS, Mehta S, Bell-Cohn A, Swenson JM, Abid S, Xin D, Lewis C, Coyle L, Wang M, Bunosso K, Maugiri M, Ruiz R, Cirillo CM, Fogal B, Grimaldi C, Vigil A, Wood C, and Ashour J

Abstract

Viral replication places oncolytic viruses (OVs) in a unique niche in the field of drug pharmacokinetics (PK) as their self-amplification obscures exposure-response relationships. Moreover, standard bioanalytical techniques are unable to distinguish the input from replicated drug products. Here, we combine two novel approaches to characterize PK and biodistribution (BD) after systemic administration of vesicular stomatitis virus pseudotyped with lymphocytic choriomeningitis virus glycoprotein (VSV-GP) in healthy mice . First: to decouple input drug PK/BD versus replication PK/BD, we developed and fully characterized a replication-incompetent tool virus that retained all other critical attributes of the drug. We used this approach to quantify replication in blood and tissues and to determine its impact on PK and BD. Second: to discriminate the genomic and antigenomic viral RNA strands contributing to replication dynamics in tissues, we developed an in situ hybridization method using strand-specific probes and assessed their spatiotemporal distribution in tissues. This latter approach demonstrated that distribution, transcription, and replication localized to tissue-resident macrophages, indicating their role in PK and BD. Ultimately, our study results in a refined PK/BD profile for a replicating OV, new proposed PK parameters, and deeper understanding of OV PK/BD using unique approaches that could be applied to other replicating vectors., Competing Interests: The authors are/were employed at Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) in Ridgefield, CT, at the time of the experiments., (© 2022.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results